Individuals vaccinated with approved HPV vaccines still run the risk of getting HPV-associated cancers. This is due to current HPV vaccine technology being unable to target all oncogenic HPVs. As a result of this incomplete coverage, cervical cancer screening is needed. In the USA, this costs up to $6B/year.
RGVax is currently a single chimeric HPV virus-like particle (VLP) platform that displays 360 copies of the highly conserved, neutralizing HPV epitope (RG1). Animal vaccination studies confirmed broad-spectrum protection (via RG-1 cross-neutralizing antibodies) against clinically relevant 27 HPVs. This dramatic improvement over licensed HPV vaccines led to a National Cancer Institute (NCI) PREVENT contract that funds GMP, toxicology, IND, and initiation for Phase 1. Human proof of concept is expected by Q1-2020. This program is primarily led by the NCI and collaborators at Johns Hopkins.